1-16 of 16
Malcolm A. Smith
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Nathan M. Kendsersky, Jarrett Lindsay, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, Eric J. Earley, Yael P. Mosse, Daniel Martinez, Jennifer Pogoriler, Kateryna Krytska, Khushbu Patel, David Groff, Matthew Tsang, Samson Ghilu, Yifei Wang, Steven Seaman, Yang Feng, Brad St. Croix, Richard Gorlick, Raushan Kurmasheva, Peter J. Houghton, John M. Maris
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2938–2946.
https://doi.org/10.1158/1078-0432.CCR-20-4221
Published: 15 May 2021
View article titled, The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
Open the PDF for The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models in another window
Includes: Supplementary data
Journal Articles

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

Kathryn Evans, JianXin Duan, Tara Pritchard, Connor D. Jones, Lisa McDermott, Zhaohui Gu, Cara E. Toscan, Narimanne El-Zein, Chelsea Mayoh, Stephen W. Erickson, Yuelong Guo, Fanying Meng, Donald Jung, Komal S. Rathi, Kathryn G. Roberts, Charles G. Mullighan, Chi-Sheng Shia, Tillman Pearce, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4493–4503.
https://doi.org/10.1158/1078-0432.CCR-19-0551
Published: 15 July 2019
View article titled, OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL
Open the PDF for OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

Yael P. Mossé, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Safgren, Hernan Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barkauskas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, Brenda J. Weigel
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3229–3238.
https://doi.org/10.1158/1078-0432.CCR-18-2675
Published: 03 June 2019
View article titled, A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Open the PDF for A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) in another window
Includes: Supplementary data
Journal Articles

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Caitlin D. Lowery, Michele Dowless, Matthew Renschler, Wayne Blosser, Alle B. VanWye, Jennifer R. Stephens, Philip W. Iversen, Aimee Bence Lin, Richard P. Beckmann, Kateryna Krytska, Kristina A. Cole, John M. Maris, Douglas S. Hawkins, Brian P. Rubin, Raushan T. Kurmasheva, Peter J. Houghton, Richard Gorlick, E. Anders Kolb, Min H. Kang, C. Patrick Reynolds, Stephen W. Erickson, Beverly A. Teicher, Malcolm A. Smith, Louis F. Stancato
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2278–2289.
https://doi.org/10.1158/1078-0432.CCR-18-2728
Published: 01 April 2019
View article titled, Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
Open the PDF for Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models in another window
Includes: Supplementary data
Journal Articles

Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL

Luke Jones, Jennifer Richmond, Kathryn Evans, Hernan Carol, Duohui Jing, Raushan T. Kurmasheva, Catherine A. Billups, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3744–3755.
https://doi.org/10.1158/1078-0432.CCR-16-2392
Published: 13 July 2017
View article titled, Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL
Open the PDF for Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL in another window
Includes: Supplementary data
Journal Articles

Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group

Ariadne H.A.G. Ooms, Samantha Gadd, Daniela S. Gerhard, Malcolm A. Smith, Jaime M. Guidry Auvil, Daoud Meerzaman, Qing-Rong Chen, Chih Hao Hsu, Chunhua Yan, Cu Nguyen, Ying Hu, Yussanne Ma, Zusheng Zong, Andrew J. Mungall, Richard A. Moore, Marco A. Marra, Vicki Huff, Jeffrey S. Dome, Yueh-Yun Chi, Jing Tian, James I. Geller, Charles G. Mullighan, Jing Ma, David A. Wheeler, Oliver A. Hampton, Amy L. Walz, Marry M. van den Heuvel-Eibrink, Ronald R. de Krijger, Nicole Ross, Julie M. Gastier-Foster, Elizabeth J. Perlman
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (22): 5582–5591.
https://doi.org/10.1158/1078-0432.CCR-16-0985
Published: 14 November 2016
View article titled, Significance of <em>TP53</em> Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group
Open the PDF for Significance of <em>TP53</em> Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group in another window
Includes: Supplementary data
Journal Articles

Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

Jennifer Richmond, Hernan Carol, Kathryn Evans, Laura High, Agnes Mendomo, Alissa Robbins, Claus Meyer, Nicola C. Venn, Rolf Marschalek, Michelle Henderson, Rosemary Sutton, Raushan T. Kurmasheva, Ursula R. Kees, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1395–1405.
https://doi.org/10.1158/1078-0432.CCR-14-2300
Published: 12 March 2015
View article titled, Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <em>MLL</em>-Rearranged Acute Lymphoblastic Leukemia
Open the PDF for Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <em>MLL</em>-Rearranged Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Gorlick, Hernan Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 819–832.
https://doi.org/10.1158/1078-0432.CCR-14-2572
Published: 16 February 2015
View article titled, Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Open the PDF for Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program in another window
Includes: Supplementary data
Journal Articles

Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts

Santi Suryani, Hernan Carol, Triona Ni Chonghaile, Viktoras Frismantas, Chintanu Sarmah, Laura High, Beat Bornhauser, Mark J. Cowley, Barbara Szymanska, Kathryn Evans, Ingrid Boehm, Elise Tonna, Luke Jones, Donya Moradi Manesh, Raushan T. Kurmasheva, Catherine Billups, Warren Kaplan, Anthony Letai, Jean-Pierre Bourquin, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4520–4531.
https://doi.org/10.1158/1078-0432.CCR-14-0259
Published: 01 September 2014
View article titled, Cell and Molecular Determinants of <em>In Vivo</em> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Open the PDF for Cell and Molecular Determinants of <em>In Vivo</em> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts in another window
Includes: Supplementary data
Journal Articles

A Proposal Regarding Reporting of In Vitro Testing Results

Malcolm A. Smith, Peter Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 2828–2833.
https://doi.org/10.1158/1078-0432.CCR-13-0043
Published: 30 May 2013
View article titled, A Proposal Regarding Reporting of <em>In Vitro</em> Testing Results
Open the PDF for A Proposal Regarding Reporting of <em>In Vitro</em> Testing Results in another window
Includes: Supplementary data
Journal Articles

The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia

Hernan Carol, Barbara Szymanska, Kathryn Evans, Ingrid Boehm, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1795–1805.
https://doi.org/10.1158/1078-0432.CCR-12-3613
Published: 02 April 2013
View article titled, The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Open the PDF for The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies

Jun S. Wei, Peter Johansson, Qing-Rong Chen, Young K. Song, Steffen Durinck, Xinyu Wen, Adam T.C. Cheuk, Malcolm A. Smith, Peter Houghton, Christopher Morton, Javed Khan
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5560–5568.
https://doi.org/10.1158/1078-0432.CCR-08-3287
Published: 31 August 2009
View article titled, microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies
Open the PDF for microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies in another window
Includes: Supplementary data
Journal Articles

Molecular Characterization of the Pediatric Preclinical Testing Panel

Geoffrey Neale, Xiaoping Su, Christopher L. Morton, Doris Phelps, Richard Gorlick, Richard B. Lock, C. Patrick Reynolds, John M. Maris, Henry S. Friedman, Jeffrey Dome, Joseph Khoury, Timothy J. Triche, Robert C. Seeger, Richard Gilbertson, Javed Khan, Malcolm A. Smith, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4572–4583.
https://doi.org/10.1158/1078-0432.CCR-07-5090
Published: 15 July 2008
View article titled, Molecular Characterization of the Pediatric Preclinical Testing Panel
Open the PDF for Molecular Characterization of the Pediatric Preclinical Testing Panel in another window
Includes: Supplementary data
Journal Articles

Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary

Richard Gorlick, Peter Anderson, Irene Andrulis, Carola Arndt, G. Peter Beardsley, Mark Bernstein, Julia Bridge, Nai-Kong Cheung, Jeffrey S. Dome, David Ebb, Thomas Gardner, Mark Gebhardt, Holcombe Grier, Marc Hansen, John Healey, Lee Helman, Janet Hock, Janet Houghton, Peter Houghton, Andrew Huvos, Chand Khanna, Mark Kieran, Eugenie Kleinerman, Marc Ladanyi, Ching Lau, David Malkin, Neyssa Marina, Paul Meltzer, Paul Meyers, Deborah Schofield, Cindy Schwartz, Malcolm A. Smith, Jeffrey Toretsky, Maria Tsokos, Leonard Wexler, Jon Wigginton, Stephen Withrow, Mason Schoenfeldt, Barry Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (15): 5442–5453.
Published: 03 December 2003
View article titled, Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: <subtitle>Meeting Summary</subtitle>
Open the PDF for Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: <subtitle>Meeting Summary</subtitle> in another window
Journal Articles

Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary

Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, Malcolm A. Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3646–3657.
Published: 01 December 2002
View article titled, Testing of New Agents in Childhood Cancer Preclinical Models: <subtitle>Meeting Summary</subtitle>
Open the PDF for Testing of New Agents in Childhood Cancer Preclinical Models: <subtitle>Meeting Summary</subtitle> in another window
Journal Articles

Where to Next with Retinoids for Cancer Therapy?

Malcolm A. Smith, Barry Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (10): 2955–2957.
Published: 01 October 2001
View article titled, Where to Next with Retinoids for Cancer Therapy?
Open the PDF for Where to Next with Retinoids for Cancer Therapy? in another window